HD-OPM Archive
Topics › Exercise & fitness

DEMFOS: metformin neither blunted nor boosted exercise and diet gains in older adults

Louis Nervegna · Aug 11, 2026 · ♥ 7 reactions · 2 comments · original Facebook post
Exercise & fitnessInsulin resistance & diabetesAging & longevity
AI summary & key facts

In a 6-month randomized trial of 114 older adults (mean age 72.8) with obesity, adding metformin to an intensive exercise and diet program neither impaired nor improved strength, aerobic capacity or mobility. The longer duration addresses earlier 3-month trials that suggested mild blunting.

We now have a well-done randomized trial testing metformin in combination with an intense exercise program in older overweight non-diabetics.

This trial ran for a long enough period of time (6 months) to separate medium-term effects from initial short-term effects. And the trial focused on functional measures of physical performance, as opposed to isolated cellular and physiological changes as in previous trials.

The results show very clearly that metformin did NOT interfere with the benefits of exercise in this trial.

“Metformin added to lifestyle intervention for physical function in older adults with obesity (DEMFOS trial): a randomised controlled trial” (Lancet, Jul 2026)

Paper · Lancet Healthy LongevityPIIS2666 7568(26)00067 Xthelancet.com

The DEMFOS randomised controlled trial (Diet and Exercise plus Metformin to Treat Frailty in Obese Seniors) found that adding metformin to an intensive exercise+diet regimen does not improve or worsen physical function in older adults with obesity, beyond the benefits of the exercise and diet alone.

The study followed 114 participants (mean age 72.8 years) over 6 months. While the structured exercise+diet intervention successfully enhanced muscle strength, aerobic capacity, and mobility, the addition of metformin did not attenuate the benefits in any detectable way. Nor did it enhance them.

Note that the DEMFOS trial ran for twice as long a duration (6 months) as previous trials reporting a mild blunting effect (~3 months).

Editorial commentary on the study published in the same issue of Lancet can be found here:

Paper · Lancet Healthy LongevityLancet Healthy Longevity articlethelancet.com

Quoting from the commentary:

The DEMFOS trial compared an intensive exercise and diet intervention against healthy lifestyle education, and tested whether adding metformin to the intensive exercise and diet intervention improved outcomes in a group of older people aged 65–85 years with obesity and physical frailty.

Frailty was operationalised using a composite measure of physical performance relevant to activities of daily living. The trial was carefully conducted and had good adherence and completion rates, and the exercise and diet intervention produced the anticipated improvements in weight and physical performance, consistent with previous findings [5]. Metformin, while well tolerated in this group, did not alter weight loss, physical performance, or quality of life.

These results reinforce that combined diet and exercise interventions remain the gold standard for older people living with obesity, even in the presence of mild to moderate physical frailty. The DEMFOS trial was designed to evaluate outcomes that matter most to older adults–namely, physical function and quality of life. For this group of older adults with obesity, metformin did not improve these outcomes and showed no benefit as an adjunct to the diet and exercise intervention.

These findings add to the wider literature examining the effect of metformin on physical performance and skeletal muscle function in older people. The current balance of evidence does not support a clinically meaningful effect of metformin on physical function or physical frailty. The DEMFOS trial and the MET-PREVENT trial in older adults with sarcopenia and frailty [6] showed no benefits of metformin use, while other trials have reported inconsistent improvements in some but not all markers of physical performance [7,8].

Previous trials in healthy older populations have shown that metformin can attenuate adaptations to both resistance and endurance training [9,10]; reassuringly, this blunting effect was not seen in the DEMFOS trial.

#metforminHD #exerciseHD #metforminexerciseHD #demfosHD

Research cited

← newer: Trials showing plaque regression: ASTEROID, GLAGOV, FOURIER,older: High-dose nattokinase combined with blood thinners may raise →